Journal of nanobiotechnology

Spleen-focused NeoPol-mL242 mRNA vaccine triggers strong T-cell responses in liver cancer models

Updated

Abstract

Essence

A spleen-targeted NeoPol-mL242 showed anti-tumor immune activity in a model.

Evidence

This was a preclinical formulation and cancer-vaccine experiment using an ionizable lipid nanoparticle platform and an HCC model.

Caveat

The evidence is limited to model-system testing, so human efficacy, delivery behavior, and safety remain unproven.

Simplified

Key numbers

~ 90%
Tumor Burden Reduction
Compared to control groups receiving no treatment.
3.5%
CD8 T-cell Infiltration Increase
CD8 T-cell activation in treated versus control groups.

Full Text

We can’t show the full text here under this license.

what lands in your inbox each week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free